Fractyl Announces First-Ever Commercial Availability of Revita for Type 2 Diabetes in Partnership with Leading UK Private Clinic

Fractyl Announces First-Ever Commercial Availability of Revita for Type 2 Diabetes in Partnership with Leading UK Private Clinic

LEXINGTON, Mass., January 28, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced its first commercial partnership with HCA Healthcare UK (United Kingdom), making its Revita® treatment commercially available for the first time for patients with type 2 diabetes. HCA Healthcare UK is the largest provider of privately funded healthcare in the UK and is part of the US-based HCA Healthcare, the world’s largest private hospital group.

Revita is a first-in-class intervention designed to target insulin resistance and metabolic disease progression by resetting key pathways in the gut that drive metabolic disease. This minimally-invasive, outpatient, endoscopic procedure is a non-drug and non-surgical alternative that has been shown in clinical trials to enhance insulin sensitivity, lower HbA1c, and reduce liver fat to create long-lasting improvements in both blood sugar control and fatty liver disease to help patients with type 2 diabetes avoid further medication escalation.1

“Our first commercial market in the UK represents a significant milestone for Fractyl. It demonstrates our evolution from developing the initial science and clinical evidence behind Revita to an organization now also focused on accelerating its availability for patients with type 2 diabetes who are seeking alternatives to current approaches,” said Harith Rajagopalan, M.D. Ph.D, co-founder and CEO of Fractyl. “This commercial availability is supported by data from several multinational clinical studies in hundreds of patients showing significant and sustained metabolic benefits from a single Revita DMR treatment.”

“We are excited to be the first medical facility in the world to be able to offer the Revita procedure to our patients with type 2 diabetes,” said Miranda Dodd, CEO of The Princess Grace Hospital, part of the HCA Healthcare UK network where the Revita procedure will be performed. “Led by a specialist team of experts, our hope is that Revita will allow patients all over the UK – and internationally – to take back control of their lives with a single treatment.”

“HCA Healthcare UK is an ideal inaugural hospital system partner in the UK market. HCA’s focus on bringing pioneering treatments to market aligns with Fractyl’s commitment to improving the health of patients suffering from metabolic diseases. We are thrilled with the strong support from physicians as well as the collaboration with HCA’s key stakeholders in making Revita available to their patients,” said Margaret Borys, Chief Commercial Officer of Fractyl. “This partnership and UK commercial availability represents an important first step in bringing Revita to patients around the world.”

The commercial launch of Revita in the UK comes following a series of global clinical trials on the procedure, involving close to 300 patients at over 20 centers across three continents. The research published to date shows five important metabolic benefits for patients: improved overall insulin sensitivity, lowered HbA1c (by nearly 1%), weight loss, improved liver health (more than 35% reduction in liver fat, a key factor in the development of NAFLD/NASH) and increased ‘good’ (HDL) cholesterol (a parameter that correlates with a reduction of CV risk).2 Furthermore, reductions in HbA1c and liver fat were observed through 24 months of follow-up from a single outpatient Revita DMR procedure, indicating the potential for Revita DMR to offer durable improvements in both type 2 diabetes and NAFLD/NASH for a full two years thus far.3 Revita DMR has been shown to be safe and well tolerated with no long term adverse events in clinical studies to date.